Menu
Recruiting NCT07439133

Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR)

Phase III Interventional Coronary Artery Disease(CAD)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: XTR004.
Who it may be relevant to
Registry conditions: Coronary Artery Disease(CAD). Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Evaluation of the Efficacy and Safety of XTR004 Injection in Detecting Blood Flow Restrictive Stenosis in Patients With Suspected or Known Stable Coronary Artery Disease: A Multicenter, Open-Label, Phase III Clinical Trial

Overview

The primary objective of this study is to evaluate the effectiveness of visual reading in XTR004 PET myocardial perfusion imaging (MPI) for detecting restrictive stenosis, using quantitative coronary angiography (QCA) and fractional flow reserve (FFR) as reference standards in patients with suspected or known coronary artery disease.

Interventions

  • Drug XTR004
    XTR004 as the experiemental drug, 99mTechnetium Sestamibi as the Active Comparator, and Coronary artery angiography as the refenrece standard

Primary outcome measures

  • Diagnostic Efficacy of XTR004 PET myocardial perfusion imaging (MPI) for detecting restrictive stenosis, using quantitative coronary angiography (QCA) and fractional flow reserve (FFR) as reference standards [Time frame: 60 days]
Secondary outcome measures (6)
  • To evaluate the differences in diagnostic efficacy between XTR004 PET MPI and MIBI SPECT MPI in detecting restrictive stenosis [Time frame: 60 days]
  • To assess differences in image quality and diagnostic certainty between XTR004 PET MPI and MIBI SPECT MPI [Time frame: 60 days]
  • To validate the effectiveness of semi-quantitative analysis in XTR004 PET MPI for the detection of restrictive stenosis [Time frame: 60 days]
  • To evaluate the diagnostic efficacy of XTR004 PET MPI in different subgroups [Time frame: 60 days]
  • To compare the differences in diagnostic performance between XTR004 PET MPI and MIBI SPECT MPI using QCA results as a reference standard [Time frame: 60 days]
  • Number of participants with treatment-related adverse events, severe adverse events as assessed by CTCAE v5.0 [Time frame: 60 days]

Eligibility criteria

Inclusion criteria

  • Participants aged 18 to 80 years, male or female.
  • Suspected or confirmed patients with stable coronary heart disease. Those suspected of having stable coronary heart disease must meet at least one of the following risk factors: hypertension, hyperlipidemia, diabetes, obesity (BMI ≥28), a history of alcohol abuse, a smoking history, a family history of coronary heart disease, postmenopausal status, or age 60 years or older.
  • Participants can communicate well with investigators, understand and comply with clinical trial requirements, voluntarily participate in the study, and sign an informed consent form.

Exclusion criteria

  • Participants with severe cardiovascular diseases, including but not limited to unstable angina (Canadian Cardiac Society (CCS) Grade III/IV angina pectoris), uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg and/or diastolic ≥110 mmHg despite long-term regular antihypertensive medication), hypotension (resting systolic blood pressure <90 mmHg), acute myocardial infarction, second or third-degree atrioventricular block, sinoatrial node disease, NYHA Class III/IV heart failure, dilated or hypertrophic cardiomyopathy, pericarditis, valvular heart disease, aortic dissection, uncontrolled severe arrhythmias, congenital heart disease, those who have undergone coronary artery bypass grafting or interventional procedures within three months, and those determined unsuitable for participation in this study by investigators;
  • Participants with severe acute or chronic pulmonary diseases (including but not limited to COPD, asthma, bronchiectasis, emphysema, pulmonary fibrosis, pulmonary embolism, pneumonia, etc.) who are determined unsuitable for participation by the investigator;
  • Participants with severe or unstable central nervous system disorders (including but not limited to unstable cerebrovascular diseases, active epilepsy, CNS infections, CNS diseases accompanied by mental disorders or motor impairments) who are determined unsuitable for participation by the investigator;
  • Participants with severe bleeding disorders or coagulation dysfunction (including but not limited to purpura, hemophilia, vitamin K deficiency, etc.) who are determined unsuitable for participation by the investigator;
  • Participants with severe liver dysfunction (including but not limited to viral hepatitis, autoimmune hepatitis, cirrhosis, liver cancer, etc.) who are determined unsuitable for participation by the investigator;
  • Participants with severe kidney impairment (including but not limited to glomerulonephritis, renal insufficiency, nephrotic syndrome, membranous nephropathy, hydronephrosis, renal cystopathy, etc.) who are determined unsuitable for participation by the investigator;
  • Participants with fever or active infectious diseases who are determined unsuitable for participation by the investigator;
  • Participants with known alcohol allergy who are determined unsuitable for participation by the investigator;
  • participants with known adenosine allergy who are determined unsuitable for participation by the investigator;
  • Participants with known iodine contrast agent allergy who are determined unsuitable for participation by the investigator;
  • Within the past 10 years, significant occupational exposure to ionizing radiation (e.g., exceeding 50 mSv/year) or exposure to radioactive substances or ionizing radiation for therapeutic/research purposes;
  • Male or women of childbearing age not using effective contraception during study participation and within 6 months post-study (effective contraception refers to sterilization, intrauterine device, condoms, abstinence, or surgical blockage of vas deferens/fallopian tubes);
  • Female participants in pregnancy or lactation
  • Individuals with claustrophobia, bipolar disorder, mental disorders, or poor compliance;
  • Participation in other investigational drug trials within 30 days prior to enrollment or planned during study;
  • Any other circumstances determined unsuitable by investigators.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Diagnostic

Study locations

China · 5 centers
  • Beijing Anzhen Hospital, Capital Medical University — Beijing
  • Beijing Tongren Hospital — Beijing
  • Peking Union Medical College Hospital — Beijing
  • The First People's Hospital of Foshan — Foshan
  • TEDA International Cardiovascular Hospital — Tianjin

Identifiers

NCT: NCT07439133 · STB-XTR004-301

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗